Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SRD5A1

Gene summary for SRD5A1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SRD5A1

Gene ID

6715

Gene namesteroid 5 alpha-reductase 1
Gene AliasS5AR 1
Cytomap5p15.31
Gene Typeprotein-coding
GO ID

GO:0000003

UniProtAcc

P18405


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
6715SRD5A1LZE4THumanEsophagusESCC2.23e-061.56e-010.0811
6715SRD5A1LZE22THumanEsophagusESCC7.00e-064.33e-010.068
6715SRD5A1LZE24THumanEsophagusESCC7.10e-052.25e-010.0596
6715SRD5A1P1T-EHumanEsophagusESCC4.94e-139.69e-010.0875
6715SRD5A1P2T-EHumanEsophagusESCC7.08e-175.08e-010.1177
6715SRD5A1P4T-EHumanEsophagusESCC1.83e-154.34e-010.1323
6715SRD5A1P5T-EHumanEsophagusESCC3.80e-083.43e-010.1327
6715SRD5A1P8T-EHumanEsophagusESCC2.47e-132.14e-010.0889
6715SRD5A1P9T-EHumanEsophagusESCC1.14e-079.67e-020.1131
6715SRD5A1P10T-EHumanEsophagusESCC6.61e-173.04e-010.116
6715SRD5A1P11T-EHumanEsophagusESCC1.67e-083.35e-010.1426
6715SRD5A1P12T-EHumanEsophagusESCC3.31e-103.60e-010.1122
6715SRD5A1P15T-EHumanEsophagusESCC2.28e-071.14e-010.1149
6715SRD5A1P16T-EHumanEsophagusESCC3.87e-162.60e-010.1153
6715SRD5A1P17T-EHumanEsophagusESCC2.08e-106.32e-010.1278
6715SRD5A1P19T-EHumanEsophagusESCC3.28e-024.93e-010.1662
6715SRD5A1P20T-EHumanEsophagusESCC1.44e-541.36e+000.1124
6715SRD5A1P21T-EHumanEsophagusESCC1.57e-134.17e-010.1617
6715SRD5A1P22T-EHumanEsophagusESCC4.99e-112.52e-010.1236
6715SRD5A1P23T-EHumanEsophagusESCC4.13e-186.28e-010.108
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0048545113ThyroidPTCresponse to steroid hormone158/5968339/187238.10e-092.00e-07158
GO:0031668113ThyroidPTCcellular response to extracellular stimulus120/5968246/187232.13e-084.91e-07120
GO:0048732113ThyroidPTCgland development193/5968436/187232.88e-086.42e-07193
GO:0001889112ThyroidPTCliver development79/5968147/187233.08e-086.82e-0779
GO:0061008112ThyroidPTChepaticobiliary system development80/5968150/187233.94e-088.55e-0780
GO:0071375110ThyroidPTCcellular response to peptide hormone stimulus136/5968290/187235.49e-081.17e-06136
GO:0031669112ThyroidPTCcellular response to nutrient levels106/5968215/187236.96e-081.44e-06106
GO:0042594111ThyroidPTCresponse to starvation98/5968197/187231.24e-072.41e-0698
GO:0032869111ThyroidPTCcellular response to insulin stimulus100/5968203/187231.70e-073.19e-06100
GO:0032868111ThyroidPTCresponse to insulin124/5968264/187231.87e-073.47e-06124
GO:0009267112ThyroidPTCcellular response to starvation80/5968156/187233.52e-075.90e-0680
GO:0031667113ThyroidPTCresponse to nutrient levels201/5968474/187237.00e-071.10e-05201
GO:0071383112ThyroidPTCcellular response to steroid hormone stimulus98/5968204/187239.83e-071.47e-0598
GO:000165517ThyroidPTCurogenital system development149/5968338/187231.41e-062.01e-05149
GO:0048511111ThyroidPTCrhythmic process131/5968298/187237.06e-068.33e-05131
GO:1901654113ThyroidPTCresponse to ketone90/5968194/187231.56e-051.65e-0490
GO:0007623111ThyroidPTCcircadian rhythm96/5968210/187231.74e-051.82e-0496
GO:0009636111ThyroidPTCresponse to toxic substance115/5968262/187232.70e-052.63e-04115
GO:0061458112ThyroidPTCreproductive system development173/5968427/187238.70e-057.23e-04173
GO:0048608111ThyroidPTCreproductive structure development170/5968424/187231.86e-041.41e-03170
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SRD5A1SNVMissense_Mutationc.460N>Cp.Gly154Argp.G154RP18405protein_codingdeleterious(0)probably_damaging(1)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
SRD5A1SNVMissense_Mutationc.688N>Cp.Ser230Prop.S230PP18405protein_codingtolerated(0.2)benign(0.145)TCGA-BH-A0DG-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapytaxotereCR
SRD5A1SNVMissense_Mutationnovelc.408N>Ap.Ser136Argp.S136RP18405protein_codingdeleterious(0.01)possibly_damaging(0.463)TCGA-AA-3869-01Colorectumcolon adenocarcinomaMale>=65III/IVChemotherapycapecitabinePD
SRD5A1SNVMissense_Mutationc.353C>Tp.Thr118Ilep.T118IP18405protein_codingtolerated(0.29)benign(0)TCGA-AD-6889-01Colorectumcolon adenocarcinomaMale>=65I/IIChemotherapyxelodaPD
SRD5A1SNVMissense_Mutationc.613N>Ap.Glu205Lysp.E205KP18405protein_codingdeleterious(0.02)possibly_damaging(0.856)TCGA-AP-A051-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
SRD5A1SNVMissense_Mutationnovelc.721N>Tp.Leu241Phep.L241FP18405protein_codingdeleterious(0.02)probably_damaging(0.917)TCGA-AP-A1DK-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SRD5A1SNVMissense_Mutationc.758N>Gp.Ile253Serp.I253SP18405protein_codingtolerated(0.22)benign(0.065)TCGA-AX-A0J0-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SRD5A1SNVMissense_Mutationrs374499334c.674N>Tp.Thr225Metp.T225MP18405protein_codingdeleterious(0)possibly_damaging(0.883)TCGA-BS-A0UV-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
SRD5A1SNVMissense_Mutationnovelc.759N>Gp.Ile253Metp.I253MP18405protein_codingtolerated(0.06)benign(0.222)TCGA-D1-A16X-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SRD5A1SNVMissense_Mutationnovelc.286G>Tp.Gly96Trpp.G96WP18405protein_codingdeleterious(0.03)benign(0.014)TCGA-05-4396-01Lunglung adenocarcinomaMale>=65III/IVUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
6715SRD5A1DRUGGABLE GENOMELEVONORGESTRELLEVONORGESTREL
6715SRD5A1DRUGGABLE GENOMEDUTASTERIDEDUTASTERIDE
6715SRD5A1DRUGGABLE GENOMEBEXLOSTERIDEBEXLOSTERIDE
6715SRD5A1DRUGGABLE GENOMEFR-146687
6715SRD5A1DRUGGABLE GENOMEFINASTERIDEFINASTERIDE
6715SRD5A1DRUGGABLE GENOMELY-266111CHEMBL29166
6715SRD5A1DRUGGABLE GENOMEFINASTERIDEFINASTERIDE
6715SRD5A1DRUGGABLE GENOMEDUTASTERIDEDUTASTERIDE
6715SRD5A1DRUGGABLE GENOMEinhibitorCHEMBL1200969DUTASTERIDE
Page: 1